Phase 3 N=286 Zalutumumab in Patients With Non-curable Head and Neck Cancer
Head and Neck Cancer · Squamous Cell Cancer
Primary: Overall Survival — 6.7; 5.2 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=376 Diabetes Self-Management Models to Reduce Health Disparities
Type 2 Diabetes
Primary: HbA1c — 8.7; 8.7; 8.6; 8.4 percentage of gycosylated HbA1c — p=0.771
N/A N=20 An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Composite Score Overall Gait After Withdrawal and Reinitiation of Dalfampridine-ER 10mg — 46.01; 51.40 units on a scale — p=0.015
Phase 3 N=596 Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients
Type 2 Diabetes
Primary: Adjusted Mean Change in HbA1c Levels — -0.58; -0.63; -0.82; -0.13 Percent — p=<0.0001
Phase 4 N=107 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
Primary: Objective Response Rate (ORR) (Investigator) — 69.8; 30.2 Percentage of Participants
Phase 3 N=113 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
Influenza
Primary: Haemagglutination Inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains. — 84.03; 40.48; 306.51; 159.02 Titer
Phase 3 N=451 Dapagliflozin DPPIV Inhibitor add-on Study
Type 2 Diabetes
Primary: Adjusted Mean Change in HbA1c Levels — 0.04; -0.45 Percent — p=<0.0001
N/A N=162 Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Breast Cancer
Primary: The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts — 60; 58; 49; 76 percentage of participants
Phase 2 N=279 Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients
Type 2 Diabetes Mellitus
Primary: Adjusted Mean Change in HbA1c Levels — -0.12; -0.10; -0.37; -0.44 percent — p=<0.0001
Phase 3 N=33 Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Learning and Memory Measures. — -3.38; -.07; -1.38; 1.93 Items recalled — p== .19
Phase 3 N=1,106 Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia
Primary: Kaplan-Meier Estimates of Overall Survival (All Randomized Participants) — 98.9; 97.7; 96.0; 93.6 Percentage of participants
Phase 2 N=129 LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response (OR) as Determined by RECIST 1.0 — 62.0 percentage of participants
N/A N=22 Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil
Hyperalgesia
Primary: Pain Tolerance — 105.3; 19.2 seconds
N/A N=151 NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r)Sensitivity Relief Study
Tooth Hypersensitivity
Primary: Immediate Sensitivity Relief. Tactile Sensitivity. — 12.36; 10.46; 0.60 grams
Phase 2 N=50 A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
Raised Intraocular Pressure
Primary: Percentage Change in Mean Intra-ocular Pressure Compared With Baseline After 4 Weeks Treatment — 0.8; -0.4; -8.1; -11.0 Percentage change — p=0.822